LIMA to LAD grafting returns patient survival to age-matched population: 20-year outcomes of MIDCAB surgery.
Lucy ManuelLaura S FongKim BettsLevi BassinHugh WolfendenPublished in: Interactive cardiovascular and thoracic surgery (2022)
MIDCAB is a safe and effective revascularization strategy which can be successfully performed in a carefully selected patient population with low morbidity and excellent long-term results. The survival of MIDCAB patients returns to that of their age/gender/year-matched counterparts within the normal population and hence should be offered as an alternative to coronary stenting when counselling patients with ischaemic heart disease.
Keyphrases
- end stage renal disease
- case report
- ejection fraction
- newly diagnosed
- chronic kidney disease
- minimally invasive
- coronary artery disease
- coronary artery
- prognostic factors
- peritoneal dialysis
- coronary artery bypass
- metabolic syndrome
- coronary artery bypass grafting
- percutaneous coronary intervention
- acute coronary syndrome
- smoking cessation
- patient reported outcomes
- antiplatelet therapy
- surgical site infection
- transcatheter aortic valve replacement